Ottobock, a Major Name in Modern Prosthetics, Heads to the Frankfurt Stock Exchange

About the Company

Ottobock has a remarkable story that began in 1919 in Thuringia. Founder Otto Bock set out after World War I to provide war veterans with functional and high-quality prostheses. This laid the foundation for a business that grew from a local manufacturer into a global leader in prosthetics and orthotics. Today, Ottobock operates in more than 60 countries and employs around 9,000 people. Its headquarters are in Duderstadt, Germany, but it also has production and R&D centres in the USA, China, and Turkey. The company has built a strong reputation not only among patients and physicians but also in sports. Thanks to in-house research and close ties with medical centres, Ottobock has established itself as a technological innovator pushing the boundaries of prosthetics. This combination of long-standing tradition, global presence, and innovative spirit makes the company one of the most attractive candidates in today’s European capital markets.

Details of the Planned IPO

As of September 16, 2025, the IPO is set to take place on the Frankfurt Stock Exchange in the Prime Standard segment. The exact date has not yet been announced, but market sources expect a window from late September to mid-October. The Näder family plans to sell part of its shares, while the company will raise about €100 million in fresh capital to fund growth and innovation. The total free float is estimated at 25–30%. The expected valuation exceeds €6 billion. According to previous reports, Deutsche Bank, Goldman Sachs, and BNP Paribas are acting as advisors. The official prospectus and price range are expected to be announced in the coming weeks.

Sector Potential

Ottobock’s IPO comes at a time when the European market for new listings is cautiously reawakening, and investors are looking for high-quality stocks with long-term potential. The healthcare sector is attractive in this regard, supported by strong structural trends. Demand for prostheses and orthoses will grow with an aging population, the rise of lifestyle-related diseases such as diabetes, and a higher incidence of injuries. The market is expected to expand at an average annual rate of around 4–5% until 2030. Exoskeletons represent another growth driver—a smaller but highly dynamic segment projected to grow at an annual rate of 16–29% until 2030. For Ottobock, this could mean a transformation from a defensive “medtech” player into an innovator with an added growth premium. Another important factor is the technological added value of combining bionics with artificial intelligence. In healthcare devices, this brings higher margins and strengthens customer and provider loyalty.

Financial Results

Ottobock has had a strong period, underscoring the attractiveness of the upcoming IPO. In 2024, the company posted revenue of over €1.6 billion, representing approximately 7% organic growth compared to 2023, while adjusted EBITDA rose to €325 million—tens of millions higher than the year before. Public sources do not disclose the company’s latest quarterly results, but reliable data is available for the first half of 2025. Ottobock entered the year in excellent shape, reporting revenue of €801 million, a 5% year-on-year increase, with organic growth reaching as much as 10%. EBITDA growth was even more impressive, up more than 30% to €180 million. The company also significantly strengthened its cash generation ability, with free cash flow nearly tripling to €93 million in the first half of the year. These figures show that Ottobock can combine steady revenue growth with rising profitability and efficiency, making it one of the strongest names preparing to list in Europe.

Conclusion

Ottobock is a textbook example of an IPO capable of attracting a wide range of investors—from conservative ones seeking a stable business to those looking for exposure to technological innovation and the emerging growth segment of exoskeletons. For the Frankfurt Stock Exchange, it represents a major addition that could also satisfy European investors’ appetite for high-quality health-tech companies.